medmix AG (MDMXF) is an industrial company specializing in high-precision delivery devices for healthcare, consumer, and industrial end-markets. The medmix news feed on Stock Titan highlights company announcements that cover strategic initiatives, segment performance, and developments across its global production footprint.
Investors and industry observers can use this page to follow corporate updates such as half-year and full-year result releases, where medmix discusses revenue trends, adjusted EBITDA margins, segment gross profit, and cash flow metrics. These communications often explain how the Healthcare segment, including Dental, Drug Delivery, and Surgery business units, and the Consumer & Industrial segment, including Industry and Beauty, are performing and evolving.
News items also include strategic partnerships and expansion projects. For example, medmix has announced a partnership with Gurit, where Gurit’s BondPro adhesive is dispensed using medmix’ MIXPAC greenLine cartridge system, reflecting a focus on sustainable packaging for industrial bonding applications. Other releases describe facility expansions, such as the second production site for Guangdong Qiaoyi Plastic Co. Ltd. in China and the enlarged GEKA do Brasil facility in São Paulo, which support the Beauty business and global customer projects.
Additionally, medmix uses media releases to outline its Growth and Efficiency program, cost measures, and strategic pivot toward high growth and high margin healthcare businesses. By reviewing these updates in one place, readers can track how medmix manages its healthcare, beauty, and industrial activities, and how its global network of 14 production sites and more than 900 active patents supports its long-term positioning. Bookmark this page to access the latest company communications and performance commentary as they are published.
medmix (MDMXF) has produced 10 million parts using Shadow Printing, its packaging decoration technology operating across three Beauty production sites.
Orders for a further 2 million parts have already been placed. The technology was introduced in Germany in October 2021, expanded to the USA in August 2025 and reached Brazil in January 2026. There are currently 43 different bottles and caps in production worldwide. Shadow Printing decorates polymer surfaces without additional foil or ink, creating matte and shiny patterns.
medmix (MDMXF) has launched the MIXPAC PiccoMix mixing tip for dental cementation delivery, adding to its MIXPAC portfolio. The company says PiccoMix provides up to 60% more applications per product than previous models, reduces dental material waste by 52% and cuts plastic waste by 33%. The tip has 12 mixing elements, compared with 8 in previous models. Available configurations include root canal and intra-oral tips, with all variants compatible with standard two-component systems and 2.5 mL, 5 mL and 10 mL cartridges.
medmix (MDMXF) received an “A” rating in CDP’s Supplier Engagement Assessment for the second consecutive year, recognizing its approach to climate action across its supply chain.
The assessment evaluates how companies manage climate-related risk in their supply chains based on CDP’s Climate Change Questionnaire, scoring governance, target-setting, Scope 3 emissions reporting and supplier engagement from A to D-. A-rated companies are named CDP Supplier Engagement Leaders and appear on CDP’s public leaderboard. medmix focuses on working with suppliers on emissions-reduction targets, transparency and climate governance across its value chain, which represents the largest share of its total emissions.
medmix (MDMXF) will support Xeris Pharmaceuticals' investigational XP-8121 once-weekly levothyroxine therapy for hypothyroidism with its D-Flex™ disposable pen injector platform.
XP-8121 combines Xeris' high-concentration XeriSol® levothyroxine formulation with an adjustable pen designed to deliver precise fixed doses. In design verification testing, D-Flex™ achieved dose accuracy that significantly exceeded ISO 11608-1 requirements for needle-based injection systems. The platform's patented dosing mechanism allows only intended dose settings, supports multiple fixed-dose configurations, delivers very small increments down to 0.005 mL, and can be adapted for volumes up to 0.75 mL. D-Flex™ has been marketed since 2023, is backed by established manufacturing and supply infrastructure, and is already used in an approved European product variant and an ongoing U.S. clinical program.
medmix (OTC:MDMXF) reported half-year 2026 revenue of CHF 214.4 million, down 4.9% reported and 1.6% organically, as softer demand in Beauty offset growth in Surgery, Dental and Industry. Healthcare segment revenue grew 0.8% organically, while Consumer & Industrial declined 3.2% organically.
Adjusted EBITDA was CHF 43.5 million, down 3.0%, but the adjusted EBITDA margin increased to 20.3%, the fifth consecutive half-year of margin expansion. Gross margin improved to 37.8%. Net income fell to CHF 0.8 million due to CHF 3.8 million restructuring costs and CHF 2.6 million impairment charges. Free cash flow rose 4.6% to CHF 12.0 million, and operating net cash flow increased 27.2% to CHF 19.4 million, supported by lower capex. medmix continued its Growth and Efficiency program towards a CHF 33 million savings target and confirmed its 2026 and mid-term guidance.
medmix (OTC:MDMXF) launched FleXa™, a customizable syringe platform for single-component dental materials. The modular system targets precision, ergonomics, and branding flexibility for dental manufacturers.
FleXa™ offers 150+ colors, custom shapes, drip-reducing plunger, 360° rotatable Grip Plate, silicone oil-free design, and four volume options compatible with 60+ dispensing tips.
medmix (OTC:MDMXF) shareholders approved all Board proposals at the Annual General Meeting on April 16, 2026. The Annual Report 2025, consolidated financial statements, Sustainability Report and appropriation of result were approved. An ordinary dividend of CHF 0.10 per share will be paid on April 22, 2026.
Rob ten Hoedt was re-elected as Chairman, KPMG was confirmed as auditor, and Proxy Voting Services GmbH was re-elected as independent proxy. AGM minutes will be published within the statutory period on the company website.
medmix (OTC:MDMXF) was named to TIME's "World's Best Companies for Sustainable Growth 2026" on March 18, 2026, one of 500 firms chosen from more than 4,000 evaluated worldwide.
The recognition cites medmix's measurable environmental steps — use of post-consumer recycled materials, improved resource efficiency and science-based emission reduction targets — and highlights its combined focus on profitable development and environmental performance.
medmix (OTC:MDMXF) reported resilient FY25 results on February 26, 2026: revenue CHF 448.0m (‑4.8% organic, ‑7.4% nominal), gross profit CHF 161.9m (36.1%, +310bps) and adjusted EBITDA CHF 89.7m (20.0%). Net income returned to profit at CHF 7.0m and operating net cash flow was CHF 40.3m. Board proposes a CHF 0.10 dividend; 2026 outlook: flat to low single‑digit organic growth and ~20% adj. EBITDA margin.
Management appointed Sven Luginbühl as CFO and confirmed the Growth & Efficiency program delivering CHF 22.6m savings to date.
medmix (MDMXF) announced two facility expansions to strengthen its Beauty segment: a new 4,000 m² production site for subsidiary Guangdong Qiaoyi in China and a major expansion of GEKA do Brasil in Cotia, Sāo Paulo.
The Qiaoyi plant adds a dedicated injection workshop, AI automation and a 3D warehouse to scale cosmetic packaging output for Asia. The GEKA expansion more than doubled the Brazilian site, insourced warehousing and increased capacity by 25%. medmix said GEKA secured one of its largest single projects, expected to deliver significant revenues in 2026–2027. Both projects emphasize automation and sustainable production.